Emergent Biosolutions (NYSE:EBS) Issues Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Emergent Biosolutions (NYSE:EBS) issued its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.03, FiscalAI reports. Emergent Biosolutions had a negative net margin of 40.16% and a negative return on equity of 0.40%. The business had revenue of $110.00 million during the quarter, compared to the consensus estimate of $123.22 million.

Here are the key takeaways from Emergent Biosolutions’ conference call:

• Full-year 2026 revenue guidance was reduced to $600 million–$645 million, reflecting lower expected MCM revenue as some U.S. government and international deliveries may shift into early 2027; commercial revenue is tracking toward the low end of the expected 20%–25% decline versus 2025.
• The company generated $122 million in year-to-date operating cash flow, ended the quarter with $226 million in liquidity, and reduced gross debt to $514 million after repurchasing $75 million of bond principal.
• Emergent expects restructuring actions to deliver approximately $40 million in annualized savings, with initial benefits beginning in the fourth quarter, and raised adjusted gross-margin guidance to 45%–47% due to operational improvements, product mix, and more stable NARCAN pricing.
• Third-quarter revenue fell to $110 million from $231 million a year earlier, while adjusted EBITDA was negative $5 million, pressured by MCM delivery timing, product mix, and competitive pricing and volume pressure in the naloxone market.
• Emergent said NARCAN remains the U.S. market leader despite new competitors, while international MCM activity reached 13 countries and contributed 22% of year-to-date MCM revenue; the company is also advancing pan-Ebola, pan-flu, AI-enabled development, and other growth programs.

Emergent Biosolutions Trading Down 2.2%

Shares of Emergent Biosolutions stock traded down $0.14 during midday trading on Wednesday, reaching $6.11. The company had a trading volume of 695,910 shares, compared to its average volume of 978,888. The stock has a fifty day moving average price of $6.52 and a 200 day moving average price of $7.99. Emergent Biosolutions has a fifty-two week low of $4.36 and a fifty-two week high of $14.06. The firm has a market cap of $313.36 million, a PE ratio of -1.20 and a beta of 2.37. The company has a debt-to-equity ratio of 1.70, a current ratio of 5.42 and a quick ratio of 2.95.

Insiders Place Their Bets

In other Emergent Biosolutions news, Director Donald Degolyer sold 17,800 shares of the firm’s stock in a transaction that occurred on Wednesday, October 7th. The shares were sold at an average price of $7.09, for a total transaction of $126,202.00. Following the completion of the transaction, the director owned 111,921 shares in the company, valued at approximately $793,519.89. This trade represents a 13.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on EBS. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Emergent Biosolutions in a research report on Wednesday, September 9th. JPMorgan Chase & Co. initiated coverage on Emergent Biosolutions in a research note on Friday, August 21st. They issued an “underweight” rating for the company. Weiss Ratings raised Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, August 21st. Finally, Zacks Research upgraded shares of Emergent Biosolutions to a “hold” rating in a report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $10.00.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company that develops, manufactures and supplies medical countermeasures for public health threats. Its portfolio has included products for protection against anthrax and smallpox, as well as treatments and emergency medicines used in overdose response and other acute-care settings.

The company has also provided contract development and manufacturing services for pharmaceutical and biotechnology companies, supporting activities such as drug substance and product manufacturing, packaging and related commercialization services.